Clin2
NCT04163562Possibly a fitRecruiting

Oral peanut treatment trial for people with peanut allergy

Peanut Allergy

Part of Immune system & allergy clinical trials.

This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
50 people
Ages
12 years to 65 years
Study type
Interventional

Who can take part

  • You must have a confirmed peanut allergy from test results (peanut blood IgE and/or a positive skin prick test).
  • You must have had allergy symptoms shortly after eating peanuts (within 60 minutes).
  • You need a positive supervised peanut challenge test at a low total dose (less than 10 grams).
  • You must carry and be trained to use an epinephrine auto-injector at home.
  • If you can become pregnant, you must use reliable birth control during the study and for 1 month after.
  • You must be willing and able to pause certain allergy medicines before skin tests and challenge tests.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07117669Recruiting· Phase 1/Phase 2
Testing a new peanut allergy treatment (ENP-501)

This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.

Aurora, Colorado
NCT03936998Recruiting· Phase 1/Phase 2
Study drug for peanut allergy to change immune response

This early-phase study tests VE416, a treatment meant to help reduce peanut allergy reactions by changing how the immune system responds. If you have documented peanut allergy, you may receive the study medicine and, for some people, take part in a supervised peanut “entry challenge.”

Boston, Massachusetts
NCT07349212Recruiting· Phase 1/Phase 2
Study of UKK-0018 for peanut allergy treatment

This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.

Camperdown, New South Wales
NCT07015996Recruiting· Phase 2
Tezepelumab for peanut allergy oral immunotherapy

This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.

Little Rock, Arkansas
NCT05695261Recruiting· Phase 2
Oral microbiome capsules for peanut allergy in teens

This Phase 2 study tests whether taking capsules made from donor gut microbes is safe and can reduce allergic reactions to peanuts. It involves peanut allergy testing and close follow-up with stool samples and check-ins.

Boston, Massachusetts
NCT07439406Not yet recruiting· Phase 2
Comparing standard and autoclaved peanut immunotherapy for peanut allergy

This study compares two types of peanut oral immunotherapy (a treatment that helps you build tolerance to peanuts) — one with standard peanuts and one with autoclaved (specially heat-treated) peanuts. It is for people with peanut allergy and aims to see which approach is safer and more effective.

Montreal, Quebec

Hear when a new Peanut Allergy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.